15Sep 2023
Mesenchymal stromal cells confer breast cancer doxorubicin resistance by producing hyaluronan

Mesenchymal stromal cells confer breast cancer doxorubicin resistance by producing hyaluronan

This study assesses key contributor to breast cancer resistance to doxorubicin - mesenchymal stromal cells (MSCs) and their secretion of hyaluronan (HA). Scientists have discovered that MSCs reduce the intratumoral accumulation of doxorubicin, making breast cancer cells more resistant to the drug. Further investigation revealed that HA plays a crucial role in mediating this resistance. Intriguingly, when hyaluronic acid synthase 2 (HAS2) was inhibited, the chemoresistant effect of MSCs was negated. Molecular dynamics simulations uncovered that HA binds to doxorubicin via hydrophobic and hydrogen bonds, hindering its entry into breast cancer cells. These findings suggest a novel mechanism of cancer cell chemoresistance and highlight the potential benefits of reducing HA levels to enhance chemotherapy efficacy.

  • #oncology

Like

Save

Share